Metformin beyond diabetes: New life for an old drug

Current Diabetes Reviews

Volumn 2, Issue 3, 2006, Pages 307-315

  Rotella, Carlo M ^a   Monami, Matteo ^a   Mannucci, Edoardo ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

HIV syndrome; Insulin resistance; Metformin; Non alcoholic steatohepatitis; Obesity; Polycystic ovary syndrome; Pregnancy

Indexed keywords

ALPHA TOCOPHEROL; ANTIANDROGEN; ANTIRETROVIRUS AGENT; CLOMIFENE; ESTROGEN; FLUTAMIDE; FOLIC ACID; GESTAGEN; METFORMIN; VITAMIN B GROUP;

ANEMIA; BLOOD CLOTTING DISORDER; CLINICAL TRIAL; DIABETES CONTROL; DIABETES MELLITUS; DIET RESTRICTION; DRUG CONTRAINDICATION; DRUG ELIMINATION; DRUG FATALITY; DRUG MECHANISM; DRUG USE; EVIDENCE BASED MEDICINE; FIBRINOLYSIS; GERIATRIC PATIENT; GLUCOSE INTOLERANCE; HEART DEATH; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIRSUTISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; LACTIC ACIDOSIS; LIPODYSTROPHY; LONG TERM CARE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OVARY POLYCYSTIC DISEASE; PERINATAL MORTALITY; PREECLAMPSIA; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; VITAMIN BLOOD LEVEL;

ANTI-OBESITY AGENTS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FATTY LIVER; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; METFORMIN; OBESITY; POLYCYSTIC OVARY SYNDROME;

EID: 33746909529     PISSN: 15733998     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339906777950651     Document Type: Review

References (122)

1. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med 2002; 137 [1]:25-33.
2. Wiernsperger NF, Bailey CJ. The antihyperglycaemic effect of metformin: therapeutic and cellular mechanisms. Drugs 1999; 58 Suppl 1:31-39.
3. Wiernsperger NF. Membrane physiology as a basis for the cellular effects of metformin in insulin resistance and diabetes. Diabetes Metab 1999; 25 [2]:110-127.
4. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes [UKPDS 34]. UK Prospective Diabetes Study [UKPDS] Group. Lancet 1998; 352 [9131]:854-865.
5. Olsson J, Lindberg G, Gottsater M, et al. Increased mortality in Type II diabetic patients using sulphonylurea and metformin in combination: a population-based observational study. Diabetologia 2000; 43 [5]:558-560.
6. Fisman EZ, Tenenbaum A, Benderly M, Goldbourt U, Behar S, Motro M. Antihyperglycemic treatment in diabetics with coronary disease: increased metformin-associated mortality over a 5-year follow-up. Cardiology 1999; 91 [3]:195-202.
7. Mannucci E, Monami M, Masotti G, Marchionni N. All-cause mortality in diabetic patients treated with combinations of sulfonylureas and biguanides. Diabetes Metab Res Rev 20 [1], 44-47. 2004.
8. Gulliford M, Latinovic R. Mortality in type 2 diabetic subjects prescribed metformin and sulphonylurea drugs in combination: cohort study. Diabetes Metab Res Rev 20 [3], 239-245. 2004.
9. Johnson J, Simpson S, Toth E, Majumdar S. Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with Type 2 diabetes. Diabet Med 22 [4], 497-502. 2005.
10. Gomez R, Mokhashi MH, Rao J, et al. Metformin adjunctive therapy with insulin improves glycemic control in patients with type 1 diabetes mellitus: a pilot study. J Pediatr Endocrinol Metab 2002; 15 [8]:1147-1151.
11. Stang M, Wysowski DK, Butler-Jones D. Incidence of lactic acidosis in metformin users. Diabetes Care 1999; 22 [6]:925-927.
12. Misbin RI, Green L, Stadel BV, Gueriguian JL, Gubbi A, Fleming GA. Lactic acidosis in patients with diabetes treated with metformin. N Engl J Med 1998; 338 [4]:265-266.
13. Gregorio F, Ambrosi F, Filipponi P, Manfrini S, Testa I. Is metfornim safe enough for ageing type 2 diabetic patients? Diabetes Metab 1996; 22 [1]:43-50.
14. Morley JE. The elderly Type 2 diabetic patient: special considerations. Diabet Med 1998; 15 Suppl 4:S41-S46.
15. Lalau JD, Race JM. Lactic acidosis in metformin therapy. Drugs 1999; 58 Suppl 1:55-60.
16. Andres E, Noel E, Schlienger JL, Blickle JF. Mild cobalamin deficiency associated with long-term metformin intake - reply. J Intern Med 2004; 255 [2]: 302-303.
17. Wulffele MG, Kooy A, Lehert P, et al. Effects of short-term treatment with metformin on serum concentrations of homocysteine, folate and vitamin B12 in type 2 diabetes mellitus: a randomized, placebo-controlled trial. J Intern Med 2003; 254 [5]:455-463.
18. Runcie J. Folate deficiency in the elderly. In: Botez M, Reynolds E, editors. Folic acid in neurology, psychiatry and internal medicine. New York: Raven, 1979: 493-499.
19. Nexo E. Variation with age of reference values for P-cobalamins. Scand J Haematol 1983; 30 [5]: 430-432.
20. Park YW, Zhu S, Palaniappan L, Heshka S, Camethon MR, Heymsfield SB. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med 2003; 163 [4]: 427-436.
21. Campbell IW, Howlett HC. Worldwide experience of metformin as an effective glucose-lowering agent: a meta-analysis. Diabetes Metab Rev 1995; 11 Suppl 1: S57-S62.
22. Bailey CJ. Biguanides and NIDDM. Diabetes Care 1992; 15[6]:755-772.
23. Lawson AA, Strong JA, Peattie P, Roscoe P, Gibson A. Comparison of fenfluramine and metformin in treatment of obesity. Lancet 1970; 2 [7670]: 437-441.
24. Munro JF, MacCuish AC, Marshall A, Wilson EM, Duncan LJ. Weight-reducing effect of diguanides in obese non-diabetic women. Br Med J 1969; 2 [648]: 13-15.
25. Fontbonne A, Andre P, Eschwege E. BIGPRO [biguanides and the prevention of the risk of obesity]: study design. A randomized trial of metformin versus placebo in the correction of the metabolic abnormalities associated with insulin resistance. Diabete Metab 1991; 17 [1 Pt 2]: 249-254.
26. Fontbonne A, Charles MA, Juhan-Vague I, et al. The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. BIGPRO Study Group. Diabetes Care 1996; 19 [9]: 920-926.
27. Charles MA, Morange P, Eschwege E, Andre P, Vague P, Juhan-Vague I. Effect of weight change and metformin on fibrinolysis and the von Willebrand factor in obese nondiabetic subjects: the BIGPRO1 Study. Biguanides and the Prevention of the Risk of Obesity. Diabetes Care 1998; 21 [11]: 1967-1972.
28. Charles MA, Eschwege E, Grandmottet P, et al. Treatment with metformin of non-diabetic men with hypertension, hypertriglyceridaemia and central fat distribution: the BIGPRO 1.2 trial. Diabetes Metab Res Rev 2000; 16 [1]: 2-7.
29. Slama G. The potential of metformin for diabetes prevention. Diabetes Metab 2003; 29 [4 Pt 2]: 6S104-6S111.
30. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. The Diabetes Prevention Program Research Group. Diabetes Care 2000; 23 [11]: 1619-1629.
31. Rodriguez-Moctezuma JR, Robles-Lopez G, Lopez-Carmona JM, Gutierrez-Rosas MJ. Effects of metformin on the body composition in subjects with risk factors for type 2 diabetes. Diabetes Obes Metab 2005; 7 [2]: 189-192.
32. Freemark M, Bursey D. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics 2001; 107 [4]: E55.
33. Kay JP, Alemzadeh R, Langley G, D'Angelo L, Smith P, Holshouser S. Beneficial effects of metformin in normoglycemic morbidly obese adolescents. Metabolism 2001; 50 [12]: 1457-1461.
34. Oleandri SE, Maccario M, Rossetto R, et al. Three-month treatment with metformin or dexfenfluramine does not modify the effects of diet on anthropometric and endocrine-metabolic parameters in abdominal obesity. J Endocrinol Invest 1999; 22 [2]:134-140.
35. Gokcel A, Gumurdulu Y, Karakose H, et al. Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity. Diabetes Obes Metab 2002; 4 [1]: 49-55.
36. Yki-Jarvinen H, Nikkila V, Makimattila S. Metformin prevents weight gain by reducing dietary intake during insulin therapy in patients with type 2 diabetes mellitus. Drugs 1999; 58 Suppl 1:53-54.
37. Paolisso G, Amato L, Eccellente R, et al. Effect of metformin on food intake in obese subjects. Eur J Clin Invest 1998; 28 [6]: 441-446.
38. Rouru J, Huupponen R, Pesonen U, Koulu M. Subchronic treatment with metformin produces anorectic effect and reduces hyperinsulinemia in genetically obese Zucker rats. Life Sci 1992; 50 [23]: 1813-1820.
39. Mannucci E, Ognibene A, Cremasco F, et al, Effect of metformin on glucagon-like peptide 1 [GLP-1] and leptin levels in obese nondiabetic subjects. Diabetes Care 2001; 24 [3]: 489-494.
40. Naslund E, Gutniak M, Skogar S, Rossner S, Hellstrom PM. Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men. Am J Clin Nutr 1998; 68 [3]: 525-530.
41. Holst JJ, Deacon CF. Inhibition of the activity of dipeptidylpeptidase IV as a treatment for type 2 diabetes. Diabetes 1998; 47 [11]:1663-1670.
42. Fruehwald-Schultes B, Oltmanns KM, Toschek B, et al. Short-term treatment with metformin decreases serum leptin concentration without affecting body weight and body fat content in normal-weight healthy men. Metabolism 2002; 51 [4]: 531-536.
43. Kowalska I, Kinalski M, Straczkowski M, Wolczyski S, Kinalska I. Insulin, leptin, IGF-I and insulin-dependent protein concentrations after insulin-sensitizing therapy in obese women with polycystic ovary syndrome. Eur J Endocrinol 2001; 144 [5]: 509-515.
44. Giugliano D, De Rosa N, Di Maro G, et al. Metformin improves glucose, lipid metabolism, and reduces blood pressure in hypertensive, obese women. Diabetes Care 1993; 16 [10]: 1387-1390.
45. Vague P, Juhan-Vague I, Alessi MC, Badier C, Valadier J. Metformin decreases the high plasminogen activator inhibition capacity, plasma insulin and triglyceride levels in non-diabetic obese subjects. Thromb Haemost 1987; 57 [3]: 326-328.
46. Scheen AJ, Letiexhe MR, Lefebvre PJ. Short administration of metformin improves insulin sensitivity in android obese subjects with impaired glucose tolerance. Diabet Med 1995; 12 [11]: 985-989.
47. Binnert C, Seematter G, Tappy L, Giusti V. Effect of metformin on insulin sensitivity and insulin secretion in female obese patients with normal glucose tolerance. Diabetes Metab 2003; 29 [2 Pt 1]: 125-132.
48. Gudbjornsdottir S, Friberg P, Elam M, Attvall S, Lonnroth P, Wallin BG. The effect of metformin and insulin on sympathetic nerve activity, norepinephrine spillover and blood pressure in obese, insulin resistant, normoglycemic, hypertensive men. Blood Press 1994; 3 [6]: 394-403.
49. Orchard TJ, Temprosa M, Goldberg R, et al. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med 2005; 142 [8]: 611-619.
50. Landin-Wilhelmsen K. Metformin and blood pressure. J Clin Pharm Ther 1992; 17 [2]: 75-79.
51. Cleeman JI, Lenfant C. The National Cholesterol Education Program: progress and prospects. JAMA 1998; 280 [24]: 2099-2104.
52. Lim SC, Tai ES, Tan BY, Chew SK, Tan CE. Cardiovascular risk profile in individuals with borderline glycemia: the effect of the 1997 American Diabetes Association diagnostic criteria and the 1998 World Health Organization Provisional Report. Diabetes Care 2000; 23 [3]: 278-282.
53. Barbieri RL, Makris A, Randall RW, Daniels G, Kistner RW, Ryan KJ. Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism. J Clin Endocrinol Metab 1986; 62 [5]: 904-910.
54. Diamanti-Kandarakis E, Kouli C, Tsianateli T, Bergiele A. Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. Eur J Endocrinol 1998; 138 [3]: 269-274.
55. Eagleson CA, Bellows AB, Hu K, Gingrich MB, Marshall JC. Obese patients with polycystic ovary syndrome: evidence that metformin does not restore sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by ovarian steroids. J Clin Endocrinol Metab 2003; 88 [11]: 5158-5162.
56. Ibanez L, Valls C, Potau N, Marcos MV, de Zegher F. Sensitization to insulin in adolescent girls to normalize hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism after precocious pubarche. J Clin Endocrinol Metab 2000; 85 [10]: 3526-3530.
57. Kazerooni T, Dehghan-Kooshkghazi M. Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome. Gynecol Endocrinol 2003; 17 [1]: 51-56.
58. Kolodziejczyk B, Duleba AJ, Spaczynski RZ, Pawelczyk L. Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome. Fertil Steril 2000; 73 [6]: 1149-1154.
59. Morin-Papunen LC, Koivunen RM, Tomas C, Ruokonen A, Martikainen HK. Decreased serum leptin concentrations during metformin therapy in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 1998; 83 [7]:2566-2568.
60. Pirwany IR, Yates RW, Cameron IT, Fleming R. Effects of the insulin sensitizing drug metformin on ovarian function, follicular growth and ovulation rate in obese women with oligomenorrhoea. Hum Reprod 1999; 14 [12]: 2963-2968.
61. Velazquez E, Acosta A, Mendoza SG. Menstrual cyclicity after metformin therapy in polycystic ovary syndrome. Obstet Gynecol 1997; 90 [3]: 392-395.
62. Genazzani AD, Battaglia C, Malavasi B, Strucchi C, Tortolani F, Gamba O. Metformin administration modulates and restores luteinizing hormone spontaneous episodic secretion and ovarian function in nonobese patients with polycystic ovary syndrome. Fertil Steril 2004; 81 [1]: 114-119.
63. Chou KH, von Eye CH, Capp E, Spritzer PM. Clinical, metabolic and endocrine parameters in response to metformin in obese women with polycystic ovary syndrome: a randomized, double-blind and placebo-controlled trial. Horm Metab Res 2003; 35 [2]: 86-91.
64. Nestler JE, Jakubowicz DJ. Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17 alpha activity and serum androgens. J Clin Endocrinol Metab 1997; 82 [12]: 4075-4079.
65. Ehrmann DA, Cavaghan MK, Imperial J, Sturis J, Rosenfield RL, Polonsky KS. Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997; 82 [2]: 524-530.
66. Kelly CJ, Gordon D. The effect of metformin on hirsutism in polycystic ovary syndrome. Eur J Endocrinol 2002; 147 [2]: 217-221.
67. Ibanez L, Valls C, Ferrer A, Ong K, Dunger DB, de Zegher F. Additive effects of insulin-sensitizing and anti-androgen treatment in young, nonobese women with hyperinsulinism, hyperandrogenism, dyslipidemia, and anovulation. J Clin Endocrinol Metab 2002; 87 [6]: 2870-2874.
68. Harborne L, Fleming R, Lyall H, Sattar N, Norman J. Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. J Clin Endocrinol Metab 2003; 88 [9]: 4116-4123.
69. Morin-Papunen L, Vauhkonen I, Koivunen R, Ruokonen A, Martikainen H, Tapanainen JS. Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study. J Clin Endocrinol Metab 2003; 88 [1]: 148-156.
70. Morin-Papunen LC, Vauhken I, Koivunen RM, Ruokonen A, Martikaenin HK, Tapanainen JS. Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. J Clin Endocrinol Metab 2000; 85 [9]: 3161-3168.
71. Morin-Papunen L, Rautio K, Ruokonen A, Hedberg P, Puukka M, Tapanainen JS. Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003; 88 [10]: 4649-4654.
72. Rautio K, Tapanainen JS, Ruokonen A, Morin-Papunen LC. Effects of metformin and ethinyl estradiol-cyproterone acetate on lipid levels in obese and non-obese women with polycystic ovary syndrome. Eur J Endocrinol 2005; 152 [2]: 269-275.
73. Ibanez L, de Zegher F. Flutamide-metformin therapy to reduce fat mass in hyperinsulinemic ovarian hyperandrogenism: effects in adolescents and in women on third-generation oral contraception. J Clin Endocrinol Metab 2003; 88 [10]: 4720-4724.
74. Ibanez L, Ong K, Ferrer A, Amin R, Dunger D, de Zegher F. Low-dose flutamide-metformin therapy reverses insulin resistance and reduces fat mass in nonobese adolescents with ovarian hyperandrogenism. J Clin Endocrinol Metab 2003; 88 [6]: 2600-2606.
75. Ibanez L, de Zegher F. Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: the key role of metformin at the start and after more than one year of therapy. J Clin Endocrinol Metab 2005; 90 [1]:39-43.
76. Cibula D, Fanta M, Vrbikova J, et al. The effect of combination therapy with metformin and combined oral contraceptives [COC] versus COC alone on insulin sensitivity, hyperandrogenaemia, SHBG and lipids in PCOS patients. Hum Reprod 2005; 20 [1]: 180-184.
77. Mitkov M, Pehlivanov B, Terzieva D. Combined use of metformin and ethinyl estradiol-cyproterone acetate in polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2005; 118 [2]: 209-213.
78. van Santbrink EJ, Hohmann FP, Eijkemans MJ, Laven JS, Fauser BC. Does metformin modify ovarian responsiveness during exogenous FSH ovulation induction in normogonadotrophic anovulation? A placebo-controlled double-blind assessment. Eur J Endocrinol 2005; 152 [4]: 611-617.
79. Yarali H, Yildiz BO, Demirol A, et al. Co-administration of metformin during rFSH treatment in patients with clomiphene citrate-resistant polycystic ovarian syndrome: a prospective randomized trial. Hum Reprod 2002; 17 [2]: 289-294.
80. De L, V, la Marca A, Ditto A, Morgante G, Cianci A. Effects of metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome. Fertil Steril 1999; 72 [2]: 282-285.
81. Parsanezhad ME, Alborzi S, Zarei A, Dehbashi S, Omrani G. Insulin resistance in clomiphene responders and non-responders with polycystic ovarian disease and therapeutic effects of metformin. Int J Gynaecol Obstet 2001; 75 [1]: 43-50.
82. Vandermolen DT, Ratts VS, Evans WS, Stovall DW, Kauma SW, Nestler JE. Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. Fertil Steril 2001; 75 [2]: 310-315.
83. Malkawi HY, Qublan HS. The effect of metformin plus clomiphene citrate on ovulation and pregnancy rates in clomiphene-resistant women with polycystic ovary syndrome. Saudi Med J 2002; 23 [6]: 663-666.
84. Malkawi HY, Qublan HS, Hamaideh AH. Medical vs. surgical treatment for clomiphene citrate-resistant women with polycystic ovary syndrome. J Obstet Gynaecol 2003; 23 [3]: 289-293.
85. la Marca A, Morgante G, Palumbo M, Cianci A, Petraglia F, De L, V. Insulin-lowering treatment reduces aromatase activity in response to follicle-stimulating hormone in women with polycystic ovary syndrome. Fertil Steril 2002; 78 [6]: 1234-1239.
86. la Marca A, Morgante G, Paglia T, Ciotta L, Cianci A, De L, V. Effects of metformin on adrenal steroidogenesis in women with polycystic ovary syndrome. Fertil Steril 1999; 72 [6]: 985-989.
87. Elter K, Imir G, Durmusoglu F. Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study. Hum Reprod 2002; 17 [7]: 1729-1737.
88. Jakubowicz DJ, Seppala M, Jakubowicz S, et al. Insulin reduction with metformin increases luteal phase serum glycodelin and insulin-like growth factor-binding protein 1 concentrations and enhances uterine vascularity and blood flow in the polycystic ovary syndrome. J Clin Endocrinol Metab 2001; 86 [3]: 1126-1133.
89. Fleming R, Harborne L, MacLaughlin DT, et al. Metformin reduces serum mullerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment. Fertil Steril 2005; 83 [1]: 130-136.
90. Seli E, Duleba AJ. Treatment of PCOS with metformin and other insulin-sensitizing agents. Curr Diab Rep 2004; 4 [1]:69-75.
91. Shobokshi A, Shaarawy M. Correction of insulin resistance and hyperandrogenism in polycystic ovary syndrome by combined rosiglitazone and clomiphene citrate therapy. J Soc Gynecol Investig 2003; 10 [2]: 99-104.
92. Ghazeeri G, Kutteh WH, Bryer-Ash M, Haas D, Ke RW. Effect of rosiglitazone on spontaneous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome. Fertil Steril 2003; 79 [3]: 562-566.
93. Ortega-Gonzalez C, Luna S, Hernandez L, et al. Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005; 90 [3]: 1360-1365.
94. Shalitin S, Phillip M. Role of obesity and leptin in the pubertal process and pubertal growth - a review. Int J Obes Relat Metab Disord 2003; 27 [8]: 869-874.
95. Guler S, Cakir B, Demirbas B, Gursoy G, Serter R, Aral Y. Leptin concentrations are related to glycaemic control, but do not change with short-term oral antidiabetic therapy in female patients with type 2 diabetes mellitus. Diabetes Obes Metab 2000; 2 [5]: 313-316.
96. Mueller WM, Stanhope KL, Gregoire F, Evans JL, Havel PJ. Effects of metformin and vanadium on leptin secretion from cultured rat adipocytes. Obes Res 2000; 8 [7]:530-539.
97. Mick GJ, Wang X, Ling FC, McCormick KL. Inhibition of leptin secretion by insulin and metformin in cultured rat adipose tissue. Biochim Biophys Acta 2000; 1502 [3]: 426-432.
98. Goldenberg N, Glueck CJ, Loftspring M, Sherman A, Wang P. Metformin-diet benefits in women with polycystic ovary syndrome in the bottom and top quintiles for insulin resistance. Metabolism 2005; 54 [1]: 113-121.
99. Kumari AS, Haq A, Jayasundaram R, Abdel-Wareth LO, Al Haija SA, Alvares M. Metformin monotherapy in lean women with polycystic ovary syndrome. Reprod Biomed Online 2005; 10 [1]: 100-104.
100. Coetzee EJ, Jackson WP. Oral hypoglycaemics in the first trimester and fetal outcome. S Afr Med J 1984; 65 [16]: 635-637.
101. Hellmuth E, Damm P, Molsted-Pedersen L. Oral hypoglycaemic agents in 118 diabetic pregnancies. Diabet Med 2000; 17 [7]: 507-511.
102. Vanky E, Salvesen KA, Heimstad R, Fougner KJ, Romundstad P, Carlsen SM. Metformin reduces pregnancy complications without affecting androgen levels in pregnant polycystic ovary syndrome women: results of a randomized study. Hum Reprod 2004; 19 [8]: 1734-1740.
103. Glueck CJ, Phillips H, Cameron D, Sieve-Smith L, Wang P. Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study. Fertil Steril 2001; 75 [1]: 46-52.
104. Glueck CJ, Wang P, Goldenberg N, Sieve L. Pregnancy loss, polycystic ovary syndrome, thrombophilia, hypofibrinolysis, enoxaparin, metformin. Clin Appl Thromb Hemost 2004; 10 [4]: 323-334.
105. Glueck CJ, Goldenberg N, Wang P, Loftspring M, Sherman A. Metformin during pregnancy reduces insulin, insulin resistance, insulin secretion, weight, testosterone and development of gestational diabetes: prospective longitudinal assessment of women with polycystic ovary syndrome from preconception throughout pregnancy. Hum Reprod 2004; 19 [3]: 510-521.
106. Marchesini G, Bugianesi E, Forlani G, et al. Non-alcoholic steatohepatitis in patients cared in metabolic units. Diabetes Res Clin Pract 2004; 63 [2]: 143-151.
107. Ludwig J, McGill DB, Lindor KD. Review: nonalcoholic steatohepatitis. J Gastroenterol Hepatol 1997; 12 [5]: 398-403.
108. Marchesini G, Brizi M, Morselli-Labate AM, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999; 107 [5]: 450-455.
109. Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001; 50 [8]: 1844-1850.
110. Marchesini G, Forlani G. NASH: from liver diseases to metabolic disorders and back to clinical hepatology. Hepatology 2002; 35 [2]: 497-499.
111. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N. Metformin in non-alcoholic steatohepatitis. Lancet 2001; 358 [9285]: 893-894.
112. Bugianesi E, Gentilcore E, Manini R, et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 2005; 100 [5]: 1082-1090.
113. Kadayifci A. Nonalcoholic steatohepatitis: role of leptin in pathogenesis and benefits of metformin in treatment. Am J Gastroenterol 2003; 98 [10]: 2330-2331.
114. Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001; 108[8]:1167-1174.
115. Lin HZ, Yang SQ, Chuckaree C, Kuhajda F, Ronnet G, Diehl AM. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med 2000; 6 [9]: 998-1003.
116. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353 [9170]: 2093-2099.
117. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12 [7]: F51-F58.
118. Miller KD, Jones E, Yanovski JA, Shankar R, Feuerstein I, Falloon J. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 1998; 351 [9106]: 871-875.
119. Hadigan C, Meigs JB, Rabe J, et al. Increased PAI-1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and insulin resistance. J Clin Endocrinol Metab 2001; 86 [2]: 939-943.
120. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996; 334 [9]: 574-579.
121. Hadigan C, Corcoran C, Basgoz N, Davis B, Sax P, Grinspoon S. Metformin in the treatment of HIV lipodystrophy syndrome: A randomized controlled trial. JAMA 2000; 284 [4]: 472-477.
122. Hadigan C, Rabe J, Grinspoon S. Sustained benefits of metformin therapy on markers of cardiovascular risk in human immunodeficiency virus-infected patients with fat redistribution and insulin resistance. J Clin Endocrinol Metab 2002; 87 [10]: 4611-4615.